Survival time and herg1 expression in AML patients. Survival from diagnosis was analyzed in 42 patients affected by AML and treated with daunorubicin-aracytine standard regimen. Data are presented in relation to the presence or absence of herg1 (number of herg1⁺ patients was 26; number of herg1⁻ patients was 16). Survival curves have been computed using the Kaplan-Meier method and statistical comparisons between curves were based on log-rank tests (P = .026).